Enfortumab vedotin
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | Nectin-4 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
1346452-25-2  |
| ChemSpider | none |
| UNII |
DLE8519RWM |
| Chemical and physical data | |
| Formula | C6642H10284N1742O2063S46 |
| Molar mass | 149.0 kg/mol |
Enfortumab vedotin[1] (ASG-22ME) is an antibody-drug conjugate[2] designed for the treatment of cancer expressing Nectin-4.[3] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker.
This drug was developed by Seattle Genetics Inc.
Results of a phase I clinical trial were reported in 2016.[2]
References
- ↑ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
- 1 2 Seattle Genetics and Agensys, an Affiliate of Astellas, Highlight Promising Enfortumab Vedotin (ASG-22ME) and ASG-15ME Phase 1 Data in Metastatic Urothelial Cancer at 2016 ESMO Congress. Oct 2016
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Enfortumab Vedotin, American Medical Association.
This article is issued from Wikipedia - version of the 10/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.